Search Results

By Caroline Hewick  / August 10, 2022  / ESMO Breast Cancer Congress 2022

Nivolumab Plus T-DXd Under Study in HER2-Expressing Metastatic Breast Cancer

In the phase Ib DS8201-A-U105 trial, the addition of the PD-1 inhibitor nivolumab to the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) did not appear to improve outcomes over T-DXd alone (based on historical controls). However, it did establish the safety of the combination,...